SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-003223
Filing Date
2021-01-29
Accepted
2021-01-29 08:35:36
Documents
14
Period of Report
2021-01-29
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tptx-8k_20210129.htm   iXBRL 8-K 47388
2 EX-99.1 tptx-ex991_26.htm EX-99.1 34395
3 GRAPHIC g022p03x5tco000001.jpg GRAPHIC 20841
  Complete submission text file 0001564590-21-003223.txt   247089

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA tptx-20210129.xsd EX-101.SCH 5800
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE tptx-20210129_lab.xml EX-101.LAB 19673
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tptx-20210129_pre.xml EX-101.PRE 11652
7 EXTRACTED XBRL INSTANCE DOCUMENT tptx-8k_20210129_htm.xml XML 3575
Mailing Address 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121
Business Address 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121 858-926-5251
Turning Point Therapeutics, Inc. (Filer) CIK: 0001595893 (see all company filings)

IRS No.: 463826166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38871 | Film No.: 21568294
SIC: 2834 Pharmaceutical Preparations